StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Somil Mehta, Sharekhan

BUYGlenmark Pharmaceuticals

bySomil Mehta, SharekhanHorizon: NA (inferred Swing (≤2wk))23 Jun 2026via CNBC Awaaz.

Entry₹2,221.2Inferred
Target₹2,300
Total upside +3.55% (call closed)
Stop loss₹2,160-2.76% risk
Exit₹2,16024 Jun 2026, 11:30 am
Stop-loss hit-2.76%
Follow Somil Mehta for new calls(25% target hit, 178 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 1 active Swing call on GLENMARK

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 4:49 am IST
2 supporting0 opposing
Supports the BUY call (2)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·23 Jun · yesterday

Glenmark Pharmaceuticals Inc., USA launched Methylene Blue Injection USP, potentially increasing revenue.

BSE · Company Update·17 Jun · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.